| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| Other Sizes |
| Targets |
As a glycosylated amino acid derivative, Fmoc-L-Asn(beta-D-GlcNAc(Ac)3)-OH does not have a defined primary drug target in the context of therapeutic development. However, as a glycopeptide building block, it may be used in research to study glycoprotein structure, protein-carbohydrate interactions, and enzyme-substrate recognition. N-linked glycosylation plays critical roles in protein folding, stability, and cell-cell recognition. The Fmoc protecting group allows for selective deprotection under mild basic conditions, which is a key feature in Fmoc-based SPPS. The acetyl groups protect the sugar hydroxyls during synthesis and can be removed after peptide assembly.
|
|---|---|
| ln Vitro |
In vitro studies on glycosylated amino acid derivatives have demonstrated their capacity to influence the release of anabolic hormones, modulate fuel availability for cellular activity, enhance mental performance under stress-related conditions, and prevent exercise-induced muscle damage. As a glycosylated asparagine derivative, this compound may be used in cell-based assays to investigate glycoprotein synthesis, protein folding, and cell-surface interactions. The compound can also be utilized in studies examining the role of glycosylation in protein function and disease.
|
| ln Vivo |
In vivo studies on glycosylated amino acid derivatives are limited as these compounds are primarily used as building blocks for glycopeptide synthesis rather than as therapeutic agents. Glycopeptides synthesized using this building block may be administered in animal studies to evaluate their effects on immune function, cell signaling, or other biological processes. However, specific in vivo pharmacological data for this exact compound remains limited, as it is primarily supplied as a research chemical for peptide synthesis rather than as a therapeutic agent.
|
| Enzyme Assay |
Non-cell-based enzyme or receptor binding assays for this compound typically involve studies with purified enzymes or lectins to evaluate the effects of glycosylation on binding affinity and enzymatic activity. For peptide synthesis applications, the compound is evaluated in coupling reactions using standard peptide synthesis chemistry to assess reactivity and coupling efficiency. The Fmoc protecting group allows for selective deprotection under mild basic conditions (e.g., piperidine). The acetyl groups can be removed after peptide assembly using mild deacetylation conditions (e.g., sodium methoxide or hydrazine).
|
| Cell Assay |
Cell-based assays for this glycosylated asparagine derivative typically utilize mammalian cell lines to evaluate glycopeptide uptake, cytotoxicity, and effects on cellular signaling. Standard protocols involve culturing cells in appropriate media at 37°C in 5% CO₂, followed by treatment with varying concentrations of the compound or glycopeptides containing it (typically 0.1-100 μM) for 24-72 hours. Cell viability is assessed using MTT or CCK-8 assays. The compound's effects on cell surface interactions and signaling can be studied using flow cytometry or microscopy.
|
| Animal Protocol |
In vivo animal studies for glycosylated peptides typically involve administration via oral gavage, intraperitoneal injection, or intravenous injection in rodent models (mice or rats). Standard protocols include dosing at ranges of 1-50 mg/kg body weight, with observations over 1-14 days depending on the study objectives. For studies evaluating the effects of glycopeptides, animals may be administered peptide formulations and monitored for therapeutic efficacy or pharmacokinetics. Pharmacodynamic assessments may include blood sampling for peptide analysis, tissue collection for histopathological examination, and monitoring of body weight. All animal studies must comply with institutional ethical guidelines.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties for this glycosylated asparagine derivative can be inferred from structurally related compounds. As a medium-sized molecule (molecular weight 695.67 g/mol), it is expected to have moderate bioavailability. The Fmoc and acetyl protecting groups are likely to be cleaved in vivo to release the glycosylated asparagine. The compound shows moderate solubility in organic solvents such as DMSO and can be formulated for in vitro studies. For in vivo administration, formulations using suitable co-solvent systems may be employed. The compound should be stored as powder at -20°C for long-term preservation. Definitive PK parameters require formal studies.
|
| Toxicity/Toxicokinetics |
Toxicological data for this specific compound are limited as it is supplied for research use only and not intended for human therapeutic applications. Glycosylated amino acid derivatives in general are considered to have low inherent toxicity. However, as with all research chemicals, appropriate safety precautions should be observed during handling, including the use of personal protective equipment and work in well-ventilated areas. The compound may cause skin and eye irritation upon contact. Acute toxicity studies in animal models would be required to establish LD₅₀ values and no-observed-adverse-effect levels. For in vitro cytotoxicity assessment, the compound can be tested in mammalian cell lines using standard MTT or LDH release assays.
|
| References | |
| Additional Infomation |
Fmoc-L-Asn(beta-D-GlcNAc(Ac)3)-OH is a glycosylated asparagine derivative featuring an Fmoc protecting group on the amino functionality and a peracetylated N-acetylglucosamine moiety attached to the asparagine side chain. N-linked glycosylation plays critical roles in protein folding, stability, and cell-cell recognition. This compound is used as a building block in Fmoc-based solid-phase peptide synthesis (SPPS) for preparing glycopeptides for studying glycoprotein structure and function. It is not an approved drug and has not undergone clinical trials; it is strictly for research purposes.
|
| Molecular Formula |
C33H37N3O13
|
|---|---|
| Molecular Weight |
683.66
|
| Exact Mass |
683.233
|
| CAS # |
131287-39-3
|
| PubChem CID |
10604596
|
| Appearance |
White to off-white solid powder
|
| LogP |
2.313
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
13
|
| Rotatable Bond Count |
16
|
| Heavy Atom Count |
49
|
| Complexity |
1240
|
| Defined Atom Stereocenter Count |
6
|
| SMILES |
CC(N[C@@H]1[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H](O[C@H]1NC(C[C@H](NC(OCC2C3=CC=CC=C3C4=CC=CC=C42)=O)C(O)=O)=O)COC(C)=O)=O
|
| InChi Key |
QOACISSHGAAMLK-MJCYOTSPSA-N
|
| InChi Code |
InChI=1S/C33H37N3O13/c1-16(37)34-28-30(48-19(4)40)29(47-18(3)39)26(15-45-17(2)38)49-31(28)36-27(41)13-25(32(42)43)35-33(44)46-14-24-22-11-7-5-9-20(22)21-10-6-8-12-23(21)24/h5-12,24-26,28-31H,13-15H2,1-4H3,(H,34,37)(H,35,44)(H,36,41)(H,42,43)/t25-,26+,28+,29+,30+,31+/m0/s1
|
| Chemical Name |
(2S)-4-[[(2R,3R,4R,5S,6R)-3-acetamido-4,5-diacetyloxy-6-(acetyloxymethyl)oxan-2-yl]amino]-2-(9H-fluoren-9-ylmethoxycarbonylamino)-4-oxobutanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 125 mg/mL (182.84 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (3.04 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (3.04 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.4627 mL | 7.3136 mL | 14.6272 mL | |
| 5 mM | 0.2925 mL | 1.4627 mL | 2.9254 mL | |
| 10 mM | 0.1463 mL | 0.7314 mL | 1.4627 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
